Published in Nat Med on July 23, 2006
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med (2008) 3.17
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 2.51
Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 2.02
Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol (2008) 1.76
An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol (2010) 1.42
Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol (2012) 1.39
The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol (2008) 1.35
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24
How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol (2010) 1.23
Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One (2012) 1.21
New insights for development of a safe and protective RSV vaccine. Hum Vaccin (2010) 1.18
Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs (2009) 1.17
Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol (2006) 1.10
Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A (2008) 1.08
Respiratory viruses and eosinophils: exploring the connections. Antiviral Res (2009) 1.06
Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med (2011) 1.02
Wanted, dead or alive: new viral vaccines. Antiviral Res (2009) 1.02
Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol (2008) 1.01
Virally delivered cytokines alter the immune response to future lung infections. J Virol (2007) 1.01
Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel) (2015) 0.99
Respiratory syncytial virus infection: mechanisms of redox control and novel therapeutic opportunities. Antioxid Redox Signal (2012) 0.97
Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol (2009) 0.97
Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice. J Immunol (2009) 0.96
C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. J Virol (2006) 0.96
Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol (2011) 0.95
Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. Viral Immunol (2009) 0.93
Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One (2012) 0.93
Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc Natl Acad Sci U S A (2013) 0.93
Immunity to RSV in Early-Life. Front Immunol (2014) 0.92
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease. Clin Vaccine Immunol (2015) 0.92
Progress in respiratory virus vaccine development. Semin Respir Crit Care Med (2011) 0.89
Antiviral B cell and T cell immunity in the lungs. Nat Immunol (2015) 0.86
Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection. Proc Natl Acad Sci U S A (2013) 0.86
Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice. PLoS One (2010) 0.83
Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice. Clin Vaccine Immunol (2009) 0.83
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev (2017) 0.83
Fixing a failed vaccine. Nat Med (2009) 0.80
Inactivation of respiratory syncytial virus by zinc finger reactive compounds. Virol J (2010) 0.80
New Approaches for Immunization and Therapy against Human Metapneumovirus. Clin Vaccine Immunol (2015) 0.79
Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol (2010) 0.79
Chemical-free inactivated whole influenza virus vaccine prepared by ultrashort pulsed laser treatment. J Biomed Opt (2015) 0.78
A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus. Arch Virol (2013) 0.78
Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III. PLoS Negl Trop Dis (2015) 0.78
A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza Other Respir Viruses (2013) 0.78
Endogenous IL-21 regulates pathogenic mucosal CD4 T-cell responses during enhanced RSV disease in mice. Mucosal Immunol (2012) 0.77
Recent vaccine development for human metapneumovirus. J Gen Virol (2015) 0.77
Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice. PLoS One (2013) 0.76
Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity. Rev Med Virol (2013) 0.76
Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci Rep (2016) 0.75
Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology. Hum Vaccin Immunother (2016) 0.75
A gas sensor array for the simultaneous detection of multiple VOCs. Sci Rep (2017) 0.75
The Helminth-Derived Immunomodulator AvCystatin Reduces Virus Enhanced Inflammation by Induction of Regulatory IL-10+ T Cells. PLoS One (2016) 0.75
Proteomic contributions to our understanding of vaccine and immune responses. Proteomics Clin Appl (2015) 0.75
Pathogens Inactivated by Low-Energy-Electron Irradiation Maintain Antigenic Properties and Induce Protective Immune Responses. Viruses (2016) 0.75
Gas Sensors Based on Molecular Imprinting Technology. Sensors (Basel) (2017) 0.75
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med (2004) 5.08
Bronchiolitis. Lancet (2006) 3.16
V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 3.00
Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat Med (2013) 2.94
Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog (2006) 2.81
Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med (2004) 2.54
High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. AIDS (2013) 2.25
Retroviral spread by induction of virological synapses. Traffic (2004) 2.19
Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1. J Virol (2007) 2.18
Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol (2010) 2.12
Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med (2002) 2.03
Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood (2008) 1.94
Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev (2005) 1.94
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol (2012) 1.90
Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity. J Virol (2005) 1.90
Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells. J Virol (2007) 1.87
Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol (2008) 1.76
Human immunodeficiency virus type 1 assembly, budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma membrane domains. J Virol (2007) 1.73
Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. Am J Respir Crit Care Med (2015) 1.65
Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. Am J Respir Crit Care Med (2014) 1.56
Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol (2011) 1.53
CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol (2010) 1.51
Open source clinical science for emerging infections. Lancet Infect Dis (2014) 1.47
Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.40
Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax (2012) 1.40
Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem (2005) 1.38
The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol (2008) 1.35
Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners. Proc Natl Acad Sci U S A (2010) 1.34
Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol (2006) 1.33
Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol (2003) 1.26
Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J Mol Biol (2010) 1.22
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One (2012) 1.22
Role of CCL5 (RANTES) in viral lung disease. J Virol (2006) 1.21
High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J Virol (2013) 1.15
Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS (2013) 1.13
The regulated secretory pathway in CD4(+) T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse. PLoS Pathog (2011) 1.13
Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose. Thorax (2013) 1.12
Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol (2005) 1.12
Development of prophylactic vaccines against HIV-1. Retrovirology (2013) 1.12
Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells. J Virol (2010) 1.09
Childhood infections, the developing immune system, and the origins of asthma. J Allergy Clin Immunol (2004) 1.05
IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol (2009) 1.04
RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity. J Infect Dis (2011) 1.03
Viral determinants of HIV-1 macrophage tropism. Viruses (2011) 1.03
The HIV-1-containing macrophage compartment: a perfect cellular niche? Trends Microbiol (2013) 1.02
Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent. J Immunol (2010) 1.02
Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease. J Immunol (2009) 1.02
Virally delivered cytokines alter the immune response to future lung infections. J Virol (2007) 1.01
Architecture and regulation of the HIV-1 assembly and holding compartment in macrophages. J Virol (2011) 1.00
Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. J AIDS Clin Res (2012) 1.00
Nosocomial pandemic (H1N1) 2009, United Kingdom, 2009-2010. Emerg Infect Dis (2011) 0.98
Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J Virol (2010) 0.97
Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine (2013) 0.96
The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung. PLoS One (2010) 0.96
Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils. PLoS One (2013) 0.95
The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respir Res (2005) 0.95
Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One (2013) 0.95
Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol (2014) 0.94
Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect (2004) 0.94
Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine (2004) 0.94
Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer. Vaccine (2010) 0.94
Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins. J Virol (2005) 0.94
New templates for HIV-1 antibody-based vaccine design. F1000 Biol Rep (2010) 0.93
Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol (2013) 0.92
Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis (2012) 0.91
Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One (2011) 0.91
Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. Vaccine (2011) 0.90
Reactive carbonyls are a major Th2-inducing damage-associated molecular pattern generated by oxidative stress. J Immunol (2011) 0.90
Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology (2013) 0.89
Using Plasmids as DNA Vaccines for Infectious Diseases. Microbiol Spectr (2014) 0.88
Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice. PLoS One (2013) 0.88
Preexposure to CpG protects against the delayed effects of neonatal respiratory syncytial virus infection. J Virol (2012) 0.88
Interfacial metal and antibody recognition. Proc Natl Acad Sci U S A (2005) 0.88
Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Res (2007) 0.88
Comparison of CATs, CURB-65 and PMEWS as triage tools in pandemic influenza admissions to UK hospitals: case control analysis using retrospective data. PLoS One (2012) 0.87
The comparative clinical course of pregnant and non-pregnant women hospitalised with influenza A(H1N1)pdm09 infection. PLoS One (2012) 0.87
Regulated secretion from CD4+ T cells. Trends Immunol (2007) 0.86
Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003. Virus Res (2004) 0.85
A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. PLoS One (2011) 0.85
Development of vaccines against common colds. Br Med Bull (2002) 0.83
Prior exposure to live Mycobacterium bovis BCG decreases Cryptococcus neoformans-induced lung eosinophilia in a gamma interferon-dependent manner. Infect Immun (2003) 0.83
SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse. J Virol (2010) 0.83
Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system. J Virol (2013) 0.83